More than 1,800 employees at the Bern facility develop and manufacture innovative biotherapies derived from human plasma.
R&D Switzerland at a glance: We are strengthening our local R&D network to contribute to our global strategic goals.
We are proud to work in the field of rare and serious diseases and to provide therapy in many areas of treatment.
We also aim to make sure that nothing holds you back from getting the therapies you need.
We operate as one integrated global R&D organization that assembles coordinated global project teams.
CSL supports Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they treat.
Every day at CSL Behring, we work as if someone's life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Popular search terms:
2021
We mark Human Rights Day as we are driven by our commitment to patients
Four European Research Programs to be Fast-Tracked in Partnership with CSL
Livia Artuso has been appointed site leader at CSL Behring Bern.
Four apprentices give us a glimpse of their day-to-day work at CSL Behring.
CSL Behring’s manufacturing site in Bern has found better ways to heat up and cool down.
CSL Limited delivered full-year net profit of $2.375 billion.
CSL Behring had the pleasure of awarding the three best Master's Degrees in Biomedical Sciences at the University of Bern.
CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune …
CSL continues to provide medicines to patients around the world.
Americas
Asia Pacific
Middle East
Europe
